JP2011500570A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500570A5 JP2011500570A5 JP2010528917A JP2010528917A JP2011500570A5 JP 2011500570 A5 JP2011500570 A5 JP 2011500570A5 JP 2010528917 A JP2010528917 A JP 2010528917A JP 2010528917 A JP2010528917 A JP 2010528917A JP 2011500570 A5 JP2011500570 A5 JP 2011500570A5
- Authority
- JP
- Japan
- Prior art keywords
- drugs
- dantrolene sodium
- solution
- group
- lyophilized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960003710 dantrolene sodium Drugs 0.000 claims 21
- LTWQNYPDAUSXBC-CDJGKPBYSA-L dantrolene sodium hemiheptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N\N1C(=O)[N-]C(=O)C1.C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N\N1C(=O)[N-]C(=O)C1 LTWQNYPDAUSXBC-CDJGKPBYSA-L 0.000 claims 21
- 229940079593 drug Drugs 0.000 claims 16
- 239000003814 drug Substances 0.000 claims 16
- 239000000243 solution Substances 0.000 claims 12
- 238000000034 method Methods 0.000 claims 8
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 claims 7
- 229940091173 hydantoin Drugs 0.000 claims 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 5
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims 5
- 238000004108 freeze drying Methods 0.000 claims 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- 229930195725 Mannitol Natural products 0.000 claims 3
- 229940127003 anti-diabetic drug Drugs 0.000 claims 3
- 239000003472 antidiabetic agent Substances 0.000 claims 3
- 239000007864 aqueous solution Substances 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 239000012931 lyophilized formulation Substances 0.000 claims 3
- 235000010355 mannitol Nutrition 0.000 claims 3
- 239000000594 mannitol Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 239000012670 alkaline solution Substances 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000006185 dispersion Substances 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 2
- 239000003193 general anesthetic agent Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 229910052739 hydrogen Chemical group 0.000 claims 2
- 239000001257 hydrogen Chemical group 0.000 claims 2
- 239000007972 injectable composition Substances 0.000 claims 2
- 239000006166 lysate Substances 0.000 claims 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 239000000021 stimulant Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- OZOMQRBLCMDCEG-CHHVJCJISA-N 1-[(z)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N/N1C(=O)NC(=O)C1 OZOMQRBLCMDCEG-CHHVJCJISA-N 0.000 claims 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010020844 Hyperthermia malignant Diseases 0.000 claims 1
- 208000018717 Malignant hyperthermia of anesthesia Diseases 0.000 claims 1
- 102000003982 Parathyroid hormone Human genes 0.000 claims 1
- 108090000445 Parathyroid hormone Proteins 0.000 claims 1
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 239000003470 adrenal cortex hormone Substances 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 239000003263 anabolic agent Substances 0.000 claims 1
- 229940070021 anabolic steroids Drugs 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 229940035674 anesthetics Drugs 0.000 claims 1
- 230000000954 anitussive effect Effects 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 230000000507 anthelmentic effect Effects 0.000 claims 1
- 229940124339 anthelmintic agent Drugs 0.000 claims 1
- 239000000921 anthelmintic agent Substances 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 230000001754 anti-pyretic effect Effects 0.000 claims 1
- 230000001362 anti-vertigo Effects 0.000 claims 1
- 239000000043 antiallergic agent Substances 0.000 claims 1
- 229940125713 antianxiety drug Drugs 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 239000003793 antidiarrheal agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000002221 antipyretic Substances 0.000 claims 1
- 229940125716 antipyretic agent Drugs 0.000 claims 1
- 239000003434 antitussive agent Substances 0.000 claims 1
- 229940124584 antitussives Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 239000003125 aqueous solvent Substances 0.000 claims 1
- 239000002968 autonomic agent Substances 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 239000000168 bronchodilator agent Substances 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000003183 carcinogenic agent Substances 0.000 claims 1
- 239000000496 cardiotonic agent Substances 0.000 claims 1
- 239000002327 cardiovascular agent Substances 0.000 claims 1
- 229940125692 cardiovascular agent Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 claims 1
- 239000006184 cosolvent Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229960001987 dantrolene Drugs 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- 239000003172 expectorant agent Substances 0.000 claims 1
- 230000003419 expectorant effect Effects 0.000 claims 1
- 229940066493 expectorants Drugs 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 239000004083 gastrointestinal agent Substances 0.000 claims 1
- 229940005494 general anesthetics Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000003589 local anesthetic agent Substances 0.000 claims 1
- 229960005015 local anesthetics Drugs 0.000 claims 1
- 201000007004 malignant hyperthermia Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- -1 p-cyanophenyl Chemical group 0.000 claims 1
- 239000000199 parathyroid hormone Substances 0.000 claims 1
- 229960001319 parathyroid hormone Drugs 0.000 claims 1
- 208000011906 peptic ulcer disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000000583 progesterone congener Substances 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 229940125723 sedative agent Drugs 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 229940000045 sensory organ drug Drugs 0.000 claims 1
- 229940125706 skeletal muscle relaxant agent Drugs 0.000 claims 1
- KSRLIXGNPXAZHD-HAZZGOGXSA-M sodium;3-[(e)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]-5-oxo-4h-imidazol-2-olate Chemical compound [Na+].[O-]C1=NC(=O)CN1\N=C\C1=CC=C(C=2C=CC(=CC=2)[N+]([O-])=O)O1 KSRLIXGNPXAZHD-HAZZGOGXSA-M 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 239000008223 sterile water Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 239000005495 thyroid hormone Substances 0.000 claims 1
- 229940036555 thyroid hormone Drugs 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97862607P | 2007-10-09 | 2007-10-09 | |
| US60/978,626 | 2007-10-09 | ||
| PCT/US2008/075406 WO2009048698A1 (en) | 2007-10-09 | 2008-09-05 | Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500570A JP2011500570A (ja) | 2011-01-06 |
| JP2011500570A5 true JP2011500570A5 (enExample) | 2011-02-17 |
| JP5406197B2 JP5406197B2 (ja) | 2014-02-05 |
Family
ID=40316940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010528917A Active JP5406197B2 (ja) | 2007-10-09 | 2008-09-05 | ダントロレン治療剤の送達を改善するための、共溶媒組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8975284B2 (enExample) |
| EP (2) | EP2219605B1 (enExample) |
| JP (1) | JP5406197B2 (enExample) |
| CA (1) | CA2702243C (enExample) |
| ES (1) | ES2583804T3 (enExample) |
| WO (1) | WO2009048698A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2069699A2 (en) * | 2006-10-03 | 2009-06-17 | Wyeth | Lyophilization methods and apparatuses |
| WO2009067175A2 (en) * | 2007-11-16 | 2009-05-28 | Nektar Therapeutics Al, Corporation | Oligomer-dantrolene conjugates and related compounds |
| WO2010126818A1 (en) * | 2009-04-27 | 2010-11-04 | Usworldmeds Llc | Intranasal delivery system for dantrolene |
| US20140072525A1 (en) * | 2012-09-07 | 2014-03-13 | Gaab, Llc | Antimicrobial preparation and methods for making and using the same |
| US9725429B2 (en) | 2013-03-15 | 2017-08-08 | Rosalind Franklin University Of Medicine And Science | Furanyl-imine and thiofuranyl-imine compounds for stabilizing ryanodine receptors from aberrant levels of calcium release |
| CA2906168C (en) * | 2013-03-15 | 2018-07-24 | Rosalind Franklin University Of Medicine And Science | Compounds for stabilizing ryanodine receptors from aberrant levels of calcium release |
| WO2015157212A1 (en) * | 2014-04-10 | 2015-10-15 | Us Worldmeds, Llc | Stable apomorphine composition and uses thereof |
| US11844782B2 (en) * | 2015-10-20 | 2023-12-19 | Spepharm Ag | Aqueous composition comprising dantrolene |
| WO2018236793A1 (en) * | 2017-06-20 | 2018-12-27 | Tarveda Therapeutics, Inc. | Targeted therapeutics |
| EP3697779B1 (en) * | 2017-10-20 | 2025-03-05 | Eagle Research Labs Limited | Dantrolene prodrugs and methods of their use |
| WO2019175761A1 (en) * | 2018-03-12 | 2019-09-19 | Orbicular Pharmaceutical Technologies Private Limited | Ready to use dantrolene compositions |
| US20210169871A1 (en) * | 2018-04-05 | 2021-06-10 | Tarveda Therapeutics, Inc. | Pharmaceutical compositions with reduced tert-butanol levels |
| JPWO2020049670A1 (ja) * | 2018-09-06 | 2021-08-12 | シミックホールディングス株式会社 | ダントロレン水性製剤及びその調製方法 |
| MA54303A (fr) | 2018-11-27 | 2021-10-06 | Eagle Res Labs Limited | Utilisation de dantrolène et de promédicaments de dantrolène pour traiter une exposition au rayonnement |
| WO2022169582A1 (en) * | 2021-02-05 | 2022-08-11 | Uswm, Llc | Compositions and methods for clear concentrated parenteral delivery of dantrolene therapeutic agents |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3415821A (en) * | 1965-09-07 | 1968-12-10 | Norwich Pharma Co | 1-(5-substituted)furfurylideneamino hydantoins and imidazolidinones |
| US4543359A (en) | 1982-10-01 | 1985-09-24 | Eaton Laboratories, Inc. | Treating cardiac arrhythmias with dantrolene sodium |
| US5158867A (en) * | 1987-08-21 | 1992-10-27 | Cryolife Inc. | Method for cryopreserving blood vessels |
| US5145769A (en) * | 1987-08-21 | 1992-09-08 | Cryolife Inc. | Method for cryopreserving blood vessels |
| US5149621A (en) | 1987-08-21 | 1992-09-22 | Cryolife, Inc. & Medical Univ. Of South Carolina | Kit for cryopreserving blood vessels |
| JPH01128923A (ja) * | 1987-11-11 | 1989-05-22 | Mikasa Seiyaku Kk | 骨格筋弛緩外用剤 |
| US5506231A (en) * | 1989-03-31 | 1996-04-09 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
| AU5015193A (en) * | 1992-09-09 | 1994-03-29 | Washington University | Prevention or treatment of sepsis with dantrolene or azumolene |
| JPH06263636A (ja) * | 1993-03-12 | 1994-09-20 | Kiyoshi Kataoka | 脳または高次神経疾患治療剤 |
| AU2266995A (en) * | 1994-04-21 | 1995-11-16 | Hisamitsu Pharmaceutical Co., Inc. | Percutaneously administrable base composition and percutaneously administrable drug composition prepared therefrom |
| US5597809A (en) | 1994-06-23 | 1997-01-28 | Massachusetts Eye & Ear Infirmary | Treatment of optic neuritis |
| US20030045587A1 (en) * | 2001-06-23 | 2003-03-06 | David Anderson | Solvent system |
| US7758890B2 (en) * | 2001-06-23 | 2010-07-20 | Lyotropic Therapeutics, Inc. | Treatment using dantrolene |
| SI1603513T1 (sl) * | 2003-03-04 | 2021-04-30 | Lyotropic Therapeutics, Inc. | Sestavki dantrolena |
| US8436190B2 (en) * | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| AR072777A1 (es) * | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
-
2008
- 2008-09-05 JP JP2010528917A patent/JP5406197B2/ja active Active
- 2008-09-05 US US12/205,303 patent/US8975284B2/en active Active
- 2008-09-05 WO PCT/US2008/075406 patent/WO2009048698A1/en not_active Ceased
- 2008-09-05 ES ES08837079.6T patent/ES2583804T3/es active Active
- 2008-09-05 CA CA2702243A patent/CA2702243C/en active Active
- 2008-09-05 EP EP08837079.6A patent/EP2219605B1/en active Active
- 2008-09-05 EP EP12187466.3A patent/EP2583670A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500570A5 (enExample) | ||
| WO2009048698A4 (en) | Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents | |
| AU2010317747B2 (en) | Use of bethanechol for treatment of xerostomia | |
| AU2011227446B2 (en) | Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form | |
| JP6612200B2 (ja) | 抗炎症性の置換シクロブテンジオン化合物のコリン塩 | |
| CN109431966B (zh) | 依达拉奉药物组合物 | |
| US20110263606A1 (en) | Solid oral dosage forms comprising tadalafil | |
| CN101784263B (zh) | 奈韦拉平的延长释放制剂 | |
| JPWO1995015751A1 (ja) | 解熱鎮痛配合剤 | |
| CN103370066A (zh) | 用于治疗癌症的包含威罗菲尼和干扰素的组合疗法 | |
| JPH10158169A (ja) | 塩化トロスピウムを含んだ医薬製剤、その調整方法および使用方法 | |
| JP2024522817A (ja) | フェニルピロールアミノグアニジン塩及び製剤 | |
| CN107530342A (zh) | 口服给药用医药组合物 | |
| TW202341973A (zh) | 治療性化合物、調配物、及其用途 | |
| JP5256739B2 (ja) | ビンカアルカロイド誘導体の安定固体分散体とその製造方法 | |
| CN102552140B (zh) | 罗格列酮的液体组合物 | |
| JPWO2022123480A5 (enExample) | ||
| JP2007508331A (ja) | オキソプラチン、その塩および誘導体を含む医薬組成物 | |
| CN114788817A (zh) | 苯海拉明药物组合物 | |
| JP2018507224A (ja) | ウマにおける発熱の処置及び防止のための組成物及び方法 | |
| CN105250221B (zh) | 一种利可瑞特干乳剂及其制备方法 | |
| WO2025026423A1 (en) | Compositions, their use and manufacture for treatment of gastrointestinal conditions | |
| CN100363001C (zh) | 一种莫西沙星胶囊剂及其制备方法 | |
| JP2020536092A (ja) | 細菌感染症の治療方法 | |
| US9717678B2 (en) | Delivery systems for improving oral bioavailability of Fenobam, its hydrates, and salts |